Nivolumab for metastatic squamous cell carcinoma of the anal canal: a retrospective study with exploratory biomarker analyses of PD-L1 Combined Positive Score and Nectin-4 and c-MET expression
This retrospective Japanese study demonstrates that nivolumab monotherapy offers efficacy and an acceptable safety profile for metastatic squamous cell carcinoma of the anal canal, while exploratory biomarker analyses suggest PD-L1 CPS as a potential predictive marker and highlight frequent Nectin-4 expression as a promising therapeutic target.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer of the anal canal is a rare disease, most often appearing as a specific type of growth called squamous cell carcinoma. While many patients are cured when the disease is found early, some develop a form that has spread to other parts of the body, known as metastatic disease. For years, the standard approach for these advanced cases involved chemotherapy, but the landscape has shifted with the arrival of a new class of drugs called immune checkpoint inhibitors. These medicines do not attack the cancer directly; instead, they remove the biological brakes that cancer cells use to hide from the body's own immune system, allowing the immune cells to recognize and destroy the tumor. One such drug, nivolumab, has become a standard treatment in Western countries for patients whose cancer has returned or spread after initial therapy. However, because this cancer is so uncommon in Japan, there was very little data on how well this treatment worked for Japanese patients, and doctors did not know which biological markers might predict who would benefit most.
A team of researchers at the National Cancer Center Hospital in Tokyo set out to fill this gap by looking back at the medical records of twelve Japanese patients who received nivolumab as a second or later treatment for metastatic squamous cell carcinoma. The study covered a five-year period, from 2020 to 2025, and focused on two main questions: how effective and safe the drug was for this specific group, and whether certain proteins on the surface of the cancer cells could serve as clues to predict the outcome. The researchers examined tumor samples taken before treatment began to measure the levels of three specific targets: a protein called PD-L1, which helps cancer cells hide from the immune system, and two other proteins, Nectin-4 and c-MET, which are being investigated as potential targets for new types of cancer-fighting drugs.
The results showed that nivolumab worked well for a significant portion of the patients. Out of the twelve individuals treated, four responded positively to the drug, with one patient achieving a complete disappearance of their detectable tumors and three others seeing their tumors shrink. This meant that one-third of the patients experienced an objective response, a rate that compares favorably with similar studies conducted in other parts of the world. The treatment also proved to be safe; while most patients experienced some side effects, such as fatigue or changes in thyroid function, none of these were severe enough to force them to stop the medication, and no patients died from the treatment itself. The median time before the disease started to grow again was just over three months, but for the patients who did respond, the benefits were long-lasting, with some remaining free of disease progression for more than two years.
Beyond the clinical outcomes, the study provided new insights into the biology of this rare cancer. The researchers found that patients with higher levels of the PD-L1 protein were more likely to respond to the treatment, suggesting that measuring this protein could help doctors identify who might benefit most from nivolumab. Perhaps even more significant was the discovery regarding Nectin-4. Every single patient whose tumor sample could be analyzed showed high levels of this protein, whereas none of them showed high levels of c-MET. This finding is important because it suggests that Nectin-4 could be a promising target for future therapies, potentially opening the door for a new type of drug that delivers a toxic payload directly to the cancer cells. In contrast, the absence of c-MET suggests that targeting that specific protein might not be a useful strategy for this disease.
While the study was limited by its small size and the fact that it looked at past records rather than a controlled experiment, it offers a clear picture of how nivolumab performs in a Japanese population. The data confirms that the drug is effective and safe for treating metastatic anal cancer in Japan, mirroring results seen elsewhere. More importantly, the biological analysis points toward a future where treatment could be tailored based on the specific proteins found on a patient's tumor. The high frequency of Nectin-4 expression, in particular, provides a strong reason to explore new drugs that target this protein, offering hope for more effective treatments for a disease that currently has very few options once it has spread.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.